Steven A Rosenberg
National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health · NCI - Surgery Branch
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven A Rosenberg as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:55 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06253520 · Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerNational Cancer Institute (NCI) · active not recruiting · Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer · principal investigator
- N/ANCT05600933 · Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentNational Cancer Institute (NCI) · enrolling by invitation · Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer · principal investigator
- Ph2NCT04536922 · Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNational Cancer Institute (NCI) · withdrawn · Metastatic HPV-16 Positive Squamous Cell Anal Cancer · principal investigator
- Ph2NCT04102436 · Non-Viral TCR Gene TherapyNational Cancer Institute (NCI) · withdrawn · Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer · principal investigator
- Ph1/Ph2NCT03480152 · Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerNational Cancer Institute (NCI) · terminated · Melanoma, Colon Cancer, Gastrointestinal Cancer · principal investigator
- Ph2NCT03412877 · Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerNational Cancer Institute (NCI) · recruiting · Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer · principal investigator
- N/ANCT03407040 · Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapyNational Cancer Institute (NCI) · terminated · Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT03300843 · Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerNational Cancer Institute (NCI) · terminated · Melanoma, Gastrointestinal Cancer, Breast Cancer · principal investigator
- Ph1NCT02489266 · In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaNational Cancer Institute (NCI) · withdrawn · Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT02153905 · T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveNational Cancer Institute (NCI) · terminated · Breast Cancer, Cervical Cancer, Renal Cancer · principal investigator
- Ph2NCT02111863 · Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Melanoma, Skin Cancer · principal investigator
- Ph1/Ph2NCT02111850 · T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveNational Cancer Institute (NCI) · completed · Cervical Cancer, Renal Cancer, Urothelial Cancer · principal investigator
- Ph2NCT02062359 · T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Melanoma · principal investigator
- Ph2NCT01967823 · T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerNational Cancer Institute (NCI) · completed · Melanoma, Meningioma, Breast Cancer · principal investigator
- N/ANCT01658917 · Collecting Solid Tumor Tissue to Identify New TreatmentsNational Cancer Institute (NCI) · completed · Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT01585428 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated CancersNational Cancer Institute (NCI) · completed · Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer · principal investigator
- Ph1NCT01585415 · Vemurafenib and White Blood Cell Therapy for Advanced MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Melanoma · principal investigator
- Ph1/Ph2NCT01583686 · CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic CancerNational Cancer Institute (NCI) · terminated · Cervical Cancer, Pancreatic Cancer, Ovarian Cancer · principal investigator
- Ph2NCT01468818 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1NCT01457131 · Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer · principal investigator
- Ph1/Ph2NCT01454596 · CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIINational Cancer Institute (NCI) · completed · Malignant Glioma, Glioblastoma, Brain Cancer · principal investigator
- Ph2NCT01369875 · Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1/Ph2NCT01369888 · Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph2NCT01319565 · Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...National Cancer Institute (NCI) · completed · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1/Ph2NCT01273181 · MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered LymphocytesNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT01236573 · Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating LymphocytesNational Institutes of Health Clinical Center (CC) · terminated · Skin Cancer, Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT01218867 · CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Melanoma, Renal Cancer · principal investigator
- Ph2NCT01174121 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerNational Cancer Institute (NCI) · recruiting · Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer · principal investigator
- Ph1/Ph2NCT00924326 · CAR T Cell Receptor Immunotherapy for Patients With B-cell LymphomaNational Cancer Institute (NCI) · completed · Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT00924287 · Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Cancer · principal investigator
- N/ANCT00923026 · Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesNational Cancer Institute (NCI) · enrolling by invitation · Melanoma, Adenocarcinoma, Carcinoma NOS · principal investigator
- Ph2NCT00704938 · Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic CancerNational Institutes of Health Clinical Center (CC) · terminated · Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00670748 · Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer · principal investigator
- Ph2NCT00612222 · Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph2NCT00610311 · Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1NCT00492440 · Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney CancerCytheris SA · terminated · Kidney Cancer, Melanoma (Skin) · study chair
- Ph2NCT00019448 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Stage IV Melanoma, Recurrent Melanoma · study chair
- Early Ph1NCT00436410 · Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerNational Institutes of Health Clinical Center (CC) · completed · Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer · study chair
- Ph2NCT00393029 · Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered LymphocytesNational Cancer Institute (NCI) · completed · Anti-p53 TCR-Gene · principal investigator
- Ph2NCT00357461 · Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaBristol-Myers Squibb · withdrawn · Melanoma (Skin) · principal investigator
- Ph2NCT00314106 · Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic MelanomaNational Cancer Institute (NCI) · completed · Metastatic Melanoma · principal investigator
- Ph2NCT00295958 · LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By SurgeryNational Institutes of Health Clinical Center (CC) · completed · Melanoma (Skin), Non-melanomatous Skin Cancer · study chair
- Ph2NCT00273910 · Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk MelanomaNational Cancer Institute (NCI) · completed · High-Risk Melanoma · principal investigator
- Ph2NCT00138229 · Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic MelanomaNational Institutes of Health Clinical Center (CC) · terminated · Melanoma (Skin) · principal investigator
- Ph2NCT00112580 · MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryBristol-Myers Squibb · completed · Pancreatic Cancer · principal investigator
- Ph2NCT00096382 · Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic MelanomaNational Institutes of Health Clinical Center (CC) · completed · Melanoma (Skin) · principal investigator
- Ph1NCT00091338 · Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · principal investigator
- Ph1NCT00091104 · Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic MelanomaNational Institutes of Health Clinical Center (CC) · completed · Melanoma (Skin) · principal investigator
- Ph1NCT00085462 · Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic MelanomaNational Institutes of Health Clinical Center (CC) · completed · Melanoma (Skin) · principal investigator
- Ph2NCT00082914 · Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerNational Cancer Institute (NCI) · completed · Kidney Cancer, Melanoma (Skin) · study chair
- Ph2NCT00079144 · Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00077532 · Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV MelanomaNational Institutes of Health Clinical Center (CC) · completed · Melanoma (Skin) · principal investigator
- Ph2NCT00072085 · Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · principal investigator
- N/ANCT00068003 · Harvesting Cells for Experimental Cancer TreatmentsNational Cancer Institute (NCI) · enrolling by invitation · Melanoma, Gastrointestinal Cancer, Metastatic Cancer · principal investigator
- Ph2NCT00019383 · Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00019721 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph1/Ph2NCT00062036 · Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic MelanomaNational Institutes of Health Clinical Center (CC) · completed · Melanoma (Skin) · principal investigator
- Ph1NCT00019175 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00059475 · Peptide Vaccination for Patients at High Risk for Recurrent MelanomaNational Cancer Institute (NCI) · completed · Melanoma · principal investigator
- Ph1/Ph2NCT00058279 · Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Intraocular Melanoma, Melanoma (Skin) · study chair
- Ph2NCT00022438 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous TreatmentNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00020358 · Vaccine Therapy in Treating Patients With MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00019994 · Vaccine Therapy in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00032045 · Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaNational Cancer Institute (NCI) · completed · Intraocular Melanoma, Melanoma (Skin) · study chair
- Ph2NCT00019669 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00020397 · Vaccine Therapy in Treating Patients With Refractory Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph2NCT00021164 · Vaccine Therapy in Treating Patients With Metastatic CancerNational Cancer Institute (NCI) · completed · Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph2NCT00019487 · Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Melanoma (Skin) · study chair
- Ph1NCT00019136 · Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial CancerNational Cancer Institute (NCI) · completed · Ovarian Cancer · study chair
- N/ANCT00001823 · Evaluation for NCI Surgery Branch Clinical Research ProtocolsNational Cancer Institute (NCI) · recruiting · Synovial Cell Cancer, Melanoma, Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Adoptive Cell Transfer Immunotherapy of CancerZIABC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $4,483,785 awarded in 2025Same name and institution; not confirmed by an ID
- Gene therapy of cancerZIABC010985 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $4,483,785 awarded in 2025Same name and institution; not confirmed by an ID
- Building on the success of the adoptive immunotherapy of cancerZIABC010763 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 · $726,880 awarded in 2020Same name and institution; not confirmed by an ID
- Surgical Consultants Collaborative Research Involving Surgical Services at NIHZIDSC003800 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2009 to 2013 · $4,475,095 awarded in 2013Same name and institution; not confirmed by an ID
- Adoptive Cell Transfer Immunotherapy of CancerZ01BC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $1,488,319 awarded in 2008Same name and institution; not confirmed by an ID
- Cell Prep CoreZ01BC010905 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $1,157,471 awarded in 2008Same name and institution; not confirmed by an ID
- Gene therapy of cancerZ01BC010985 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $1,488,319 awarded in 2008Same name and institution; not confirmed by an ID
- Surgical Consultants & Collaborative Research Involving Surgical Services at NIHZ01SC003800 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $6,666,513 awarded in 2008Same name and institution; not confirmed by an ID
- The Immunotherapy of Animal and Human CancerZ01SC003811 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2007 · $3,172,648 awarded in 2007Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:55 UTC. The ranking covers the 200 most relevant of 189 PubMed records, and a shared surname and initials can bring in a namesake. All 189 on PubMed
- Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.N Engl J Med · 19852,529 citationsRCR 53.1
- 2,446 citationsRCR 71.3
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.N Engl J Med · 20032,184 citationsRCR 45.6
- Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science · 20022,180 citationsRCR 37.3
- 2,095 citationsRCR 39.8
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res · 20111,739 citationsRCR 38.1
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med · 19981,503 citationsRCR 30.0
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.J Clin Oncol · 20111,338 citationsRCR 29.4
- 1,327 citationsRCR 38.4
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.J Clin Oncol · 20051,284 citationsRCR 23.9